Хронический гепатит список литературы

Содержание статьи

Современный подход к адекватной терапии хронических гепатитов: Список литературы

Комментарии

М. Г. Романцов, Т. В. Сологуб, Л. Г. Горячева

Предыдущий раздел | Содержание

Список литературы

1. Бондаренко А. Н. Этиотропная терапия вирусных гепатитов у лиц, употребляющих наркотик // Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова. 2006. № 4. С. 168-174.
2. Бондаренко А. Н. Влияние циклоферона на активность системы протеолиза у больных вирусными гепатитами, употребляющих наркотики // Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова. 2005. № 2. С. 37-42.
3. Ершов Ф. И. Пять десятилетий интерферона // Интерферону 50 лет: материалы юбилейной конференции. Москва. 2007. С. 11-35.
4. Зарубина И. В. Биохимические механизмы гипоксического повреждения клетки // Молекулярная фармакология антигипоксантов. Издательство Н-Л. 2007. С. 17-82.
5. Киселев О. И. Интерферон-гамма: новый цитокин в клинической практике / Ершов Ф. И. Москва. 2007. С. 15-46.
6. Кожока Т. Г. Субстраты энергетического обмена //Лекарственные средства в фармакотерапии патологии клетки. Москва. 2007. С. 95-97.
7. Кремень Н. В. Индивидуальная чувствительность к препаратам интерферона для повышения эффективности терапии больных хроническим гепатитом С // Инфекции в практике клинициста. Антибактериальная и антивирусная терапия на догоспитальном и госпитальном этапах: материалы научной конференции. Харьков. 2007. С. 80-83.
8. Кремень Н. В. Качество жизни и психологические особенности больных с хроническим поражением печени // Фармакотерапевтический альманах. 2009. № 3. С. 69-76.
9. Малеев В. В. Хронический гепатит С: возможности и перспективы противовирусной терапии // Вестник СПбГМА им. И. И. Мечникова. 2008; 3 (28): 37-41.
10. Наровлянский А. Н. Иммунопатогенетические аспекты назначения иммунотропных препаратов при HCV-инфекции // Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова. 2008. № 3. С. 160-164.
11. Наследникова И. О. Иммунорегуляторные цитокины и хронизация вирусного гепатита С: клинико-иммунологические параллели // Клиническая медицина. 2005. № 9. С. 40-44.
12. Носик Н. Н. Интерфероны и противовирусный иммунитет // Интерферону 50 лет: материалы юбилейной конференции. Москва. 2007. С. 72-81.
13. Радченко В. Г. Терапия хронического вирусного гепатита С сочетанием рекомбинантного интерферона-α2b и индуктора интерферонов — циклоферона // Вестник СПбГМА им. И. И. Мечникова. 2002. № 1-2. С. 123-128.
14. Романцов М. Г. Роль цитокинов в противовирусном иммунитете при хроническом вирусном гепатите С // Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова. 2007. № 4. С. 207-215.
15. Романцов М. Г. Иммуномодуляторы в «золотом стандарте» терапии хронического вирусного гепатита С // Антибиотики и химиотерапия. 2008. № 5-6. С. 18-22.
16. Сологуб Т. В. Изучение фармакотерапевтической эффективности, безопасности с оценкой риска неблагоприятных исходов включения ремаксола в терапию хронических поражений печени // Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова. 2009. № 2. С. 112-116.
17. Семеняко Н.А. Клинико-морфологическая и иммуносерологическая характеристика малосимптомных форм HCV-инфекции // Автореф. дисс. … к. м. н. Санкт-Петербург. 2009. 22 с.
18. Суханов Д. С. Антиоксидантная активность ремаксола на модели лекарственного поражения печени // Вестник Санкт-Петербургской государственной медицинской академии им. И. И. Мечникова. 2008. № 4. С. 127-132.
19. Тихомирова И. В. Цитокины Thl и Th2 при вирусных гепатитах В и С у подростков // Цитокины и воспаление. 2002. № 2. С. 132-136.
20. Balan Y., Rosati М., Anderson М., Rakela J. Succesf ul treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegy-lated interferon therapy // Dig. Dis. Sci. 2006. Vol. 51. N 5. P. 956-959.
21. Balfor L., Cooper C., Kowa J. Depression and cigarette smoking independently relate to reduced health-related quality of life amang living hepatitis С // Gastroenterology-2006. Vol. 2. N 2. P. 520-528.
22. Bernstein D., Kleimann L., Barker C. Relationship of healt-related quality of life to treatment adherence and substained resoonse chronic hepatitis С // Hepatology. 2002. Vol. 35. N 3. P. 704-708.
23. Biron Ch., Gazzinelli R. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome // Current Opinion in Immunology. 1995. Vol. 7. P. 485-496.
24. Bizolon T. Triple antiviral therapy with amantadin for IPN-ribavirin non-responders with recurrent posttransplantation hepatitis C// Transplantation. 2005. Vol. 15. P. 325-329.
25. Brok J. Elfects of adding ribavirin to interferon to treat chronic hepatitis С infection: a systematic review and meta-analysis of randomized trials // Arch. Intern. Med. 2005. Vol. 165. P. 2206-2212.
26. Castera L., Constant A., Bernard P. H. Psychological in pact of chronic hepatitis C: comprassion with other stressful live events // World J. Gastroent. 2006. Vol. 12. N 10. P. 545-550.
27. Cornberg M., Deterding K., Manns M. Present and future therapy for hepatitis С virus // Expert Rev. Anti. Infect. Ther. 2006. Vol. 4. N 5. P. 781-793.
28. Dan A. A., Martin I., Crone C. Depression, anemia and health-related quality of life in chronic hepatitic С // J. Hepatol. 2006. Vol. 44. N 3. P. 491-498.
29. Dan A. A., Crone C., Wise T. N. Anger experiences among hepatitis С patient: relationship to depressive symptoms and health-related quality of life // Psychosomatics. 2007. Vol. 48. N 3. P. 223-229.
30. Danoff A., Khan О., Wan D. W. Sexual dysfunction in higly prevalent amang men with chronic hepatitis С virus in fection and negatively impacts health-related quality of life // Am. J. Gastroenterol. 2006. Vol. 101. N 6. P. 1235-1243.
31. Hoofnagle J., Seeff L. Peginterferon and ribavirin for chronic hepatitis С // N. Engl. J. Med. 2006. Vol. 355. N 23. P. 2444-2451.
32. Jacobson I. M., Gonzalez S. A., Ahmed F. A randomized trial of pegy-lated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis С // Am. J. Gastroenterol. 2005. Vol. 100. N 11. P. 2453-2462.
33. Katayama K., Kasahara A., Sasaki Y. Immunological response to interferon-gamma priming prior to interferon alpha treatment in refractory chronic hepatits С in relation to viral clearance // J. Viral. Hepat. 2001. Vol. 8. N 3. P. 180-185.
34. Laursen A., Vilstrup H. Treatment of chronic hepatitis C-ribavirin plus interferon. An analysis of a systematic Cochrane review // Ugeskr Laeger. 2006. Vol. 168. N 48. P. 4209-4212.
35. Lang C. A., Caonrad S., Garett L. Symptom prevalence and clustering of symptoms in people living with cronic hepatitis С infection // J. Pain. Sympthom. Manag. 2006. Vol. 31. N 4. P. 335-344.
36. Larrey D., Couzigou P., Denis J. Chronic hepatitis C: management side effects of treatment // Gastro. Clin. Biol. 2007. Vol.31. N 3. P. 420-428.
37. Malyszczak K» Inglot M., Pawlowski X. Depressive symptoms during treatment with interferon for HCV infection // Psychiatr. Poland. 2006. Vol. 40. N 4. P. 799-808.
38. Manns M., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy side effects, and complications // Gut. 2006. Vol. 55. N 9. P. 1350-1359.
39. Milazzo L. Thalidomide in the treatment of chronic hepatitic С unresponsive to alpha-interferon and ribavirin // Am. J. Gastroenterol. 2006. Vol. 101. P. 399-402.
40. Mascolini M. HIV, HBV and HCV in Europe: border crossing and buried tombs // IAPA. 2005. Vol. 11. N 12. P. 386-403.
41. Milazzo L. Biazin M. Gatti N. Thalidomide in the treatment of chronic hepatitis С unresponsive to alpha-interferon and ribavirin // Am. J. Gastroenterol. 2006. Vol. 101. N 2. P. 399-402.
42. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense // Science. 1994. 264. P. 1918-1921.
43. Musch E., Hogemann В., Gerritzen A. Phase II clinical trial of combined natural interberon-beta plus recombinant interferon-gamma treatment of chronic hepatitis В // Hepatogastroenterology. 1998. Vol. 45. N 24. P. 2282-2294.
44. Nacamura T. Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis С // Nippon Ganka Gakkai Zassshi. 2005. Vol. 109. P. 748-752.
45. Olveria A. Interferon, ribavirine and amantadine in prior nonre-sponders to interferon and ribavirin therapy with chronic hepatitis С (genotype 1) // Gastroenterol. Hepatol. 2003. Vol. 26. P. 465-468.
46. Ozkan M., Corapcioglu A., Bakioglu I. et al. Psychiatric morbidity and its effect on the quality of life patients with chronic hepatitis С // Int. J. Psychiatry. 2006. Vol. 36. N 3. P. 283-297.
47. Presti R. M., Popkin D. L., Connie M. Novel cell type-specific antiviral mechanism of interferon gamma action in macrofages // J. Exp. Med. 2001. Vol. 123. N 4. P. 483-496.
48. Rowan P. J., Al-Jurdi R., Tavakovli S. Physical and psychosocial contributions to quality of life in veterans with hep atitis С not on antiviral therapy // J. Clin. Gastroenterol. 2005. Vol. 39. N 8. P. 731-736.
49. Samuel С. E. Antiviral actions of interferons // Clinical Microbiology review. 2001. Vol. 123. N 1. P. 209-216
50. Strauss E., Dias Teixera M. C. Quality oflife in hepatitis С // Liver Int. 2006. Vol. 26. N 7. P. 755-765.
51. Taliani G., Ruccin P., Biliotti E. Therapy expectations and physical comorbidity affect quality oflife in chronic hepatitis С virus infection // J. Viral. Hepatoogy.. 2007. Vol. 14. N 12. P. 875-879.
52. Shiffman M. L. Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders // Curr. Gastroenterol. Rep. 2006. Vol. 8. P. 46-52.
53. Von Wagner M» Lee J. H» Kronenberger B. Impared health-related quality of life in patients with cronic hepatitis Cand persistently normal aminotransferase levels// J. Viral. Hepatology. 2006. Vol. 13. N 12. P. 828-834.
54. Wang Т., Seiwert S. Immunomodulatory activities of IFN-gammalb in the treatment of chronic HCV infections // J. Interferon Cytokine Res. 2006. Vol. 26. N 7. P. 473-483.
55. Younossi Z» Kallman X., Kincaid J. The effects of HCV management on healt-related quality of life // Hepatology-2007. Vol. 45. N 3. P. 806-816.

Предыдущий раздел | Содержание

Вирусный гепатит С: Список литературы

Комментарии

ЛИТЕРАТУРА

1. Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
2. Sherlock S. Viral hepatitis C. Curr Opin Gastroenterol 1993; 9: 341-348.
3. Hopt U, Moller В , Kuther D, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis С virus (HCV). J Hepatol 1990; 10: 69-76.
4. Hammel P, Marcellin P, Martinot-Peignoux M, et al. Etiology of chronic hepatitis in France: predominant role of hepatitis С virus. J Hepatol 1994; 21: 618-623.
5. Tabor E, Kobayashi. Hepatitis С virus, a causative infectious agent of non-A, non-B hepatitis: Prevalence and structure — summary of a conference on hepatitis С virus as a cause of hepatocellular carcinoma. J Nati Cancer Inst 1992; 84: 86-90.
6. Van der Poel CL, Cuypers HT, Reesink HW. Hepatitis С virus six years on. Lancet 1994; 344: 1475-1479.
7. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis С virus genotypes: An investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19:13-18.
8. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis С virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc Nati Acad Sci USA 1993; 90: 8234-8238.
9. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis С viral genotypes. Hepatology 1994;19:1321-1324.
10. Koziel MJ, Liang TJ. Vaccination against hepatitis С virus infection: Miles to go before we sleep. Hepatology 1994;20:758-760.
11. Tokushige K, Pachuk C, Wakita T, et al. Development and immune response to HCV-core DNA vaccine constructs (Abst 535). Hepatology 1994;20:230A.
12. Hitomy Y, McDonell WM, Askari F. HCV core protein as a possible vaccine (Abst 536). Hepatology 1994;20:230A.
13. Overby LR. Hepatitis C: Looking at a virus that hasn’t been seen .Gut 1993;34 (Suppl 2):S6-S9.
14. Schmilovitz-Weiss H, Levy M, Thompson N, Dusheiko G. Viral markers in the treatment of hepatitis В and C. Gut 1993;34 (Suppl 2): S26-S35.
15. Shimisu Y, Hijkata M, lwamoto A, Alter H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutants. J Virol 1994;68:1494-1500.
16. Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A,non-B hepatitis. Science 1989;244:362-364.
17. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engi J Med 1989;321:1494-1500.
18. Esteban Jl, Esteban R, Viladomiu I, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;ii:294-297.
19. Van der Poel CL, Reesink HW, Leiie PN, et al. Anti-hepatitis C antibodies and non-A, non-B posttransfusion hepatitis in the Netherlands. Lancet 1989;ii:297-298.
20. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990:264: 2231-2235.
21. Ellis LA, Brown D, Conradie JD, et al. Prevalence of hepatitis C in South Africa: Detection of anti-HCV in recent and stored serum. J Med Virol 1990;32:249-251.
22. McFarlane IG, Smith HM, Johnson PJ, et al. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive results? Lancet 1990:335:754-757.
23. LokASF, Ma OCK, Chan TM, et al. Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera. Hepatology 1991;14:756-762.
24. Aach RD, Stevens CE, Hollinger BF, et al. Hepatitis C virus infection in posttransfusion hepatitis. An analysis with first second-generation assays. N Engi J Med 1991:325:1325-1329.
25. McHutchison JG, Person JL, Govindarajan S, et al. Improved detection of hepatitis C virus antibodies in high-risk populations. Hepatology 1992;15:19-25.
26. Katayama T, Mazda T, Kikuchi S, et al. Improved serodiagnosis of non-A, non-B hepatitis by an assay detecting antibody to hepatitis C virus core antigen. Hepatology 1992;15:391-394.
27. Dourakis S, Brown J, Kumar U, et al. Serological response and detection of viraemia in acute hepatitis C infection. J Hepatology 1992;14:370-376.
28. Nakatsuji Y, Matsumoto A, Tanaka E, Ogata H, Klyosawa K. Detecticm of chronic hepatitis С virus infection by four diagnostic systems: First-generation and second-generation enzyme-linked immunosorbent assay, second-generation recombinant immunoblot assay and nested polymerase chain reaction analysis. Hepatology 1992;16:300-305.
29. Barrera JM, Ercilla MG, Francis B, et al. Detection of anti HCV antibodies (third-generation test) and HCV-RNA in seroconversion of acute hepatitis С (Abst 563). Hepatology 1994:20:237A.
30. Lee SR, Page E, Francis B, et al. Improved detection of anti-HCV in patients with liver disease by third-generation HCV assays (Abst 575). Hepatology 1994:20:240A.
31. Ebeling F, Naukkarinen R, Leikola J. Recombinant immunoblot assay for hepatitis С virus antibody as predictor of infectivity (letter). Lancet 1990:335:982-983.
32. Tilston P, Morris DJ, Klapper KE, et al. Commercial assay for hepatitis С virus RNA. Lancet l994;344:201-202.
33. Garson JA, Ring C, Nuke P, Tedder RS. Enhanced detection by PCR of hepatits С virus RNA (letter). Lancet 1990;336:878-879.
34. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis С virus replication in non-A, non-B hepatitis. N Engi J Med 1991:325:98-104.
35. Alter MJ. Transmission of hepatitis С virus- route, dose, and liter. N Engi J Med 1994:330:784-786.
36. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis С virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
37. Thiers V, Pol S, Reijasse D, et al. Comparative evaluation of HCV viremia by using quantitative PCR and branched chain DNA assays in HCV chronically infected haemophiliacs (Abst 586). Hepatology 1994;20:243A.
38. Kolberg J, Detmer J, Joh J, et al. Comparison of quantitation of six hepatitis C genotypes using Quantiplex HCV RNA assay (Abst 579). Hepatology 1994:20:241A.
39. Marrone A, Kleiner D, Mahaney K, et al. The significance of HCV RNA: Analysis by semi-quantitative in-situ hybridisation (Abst 558). Hepatology 1994;20:236A.
40. Sherlock S. Treatment of chronic hepatitis. Curr Opin Gastroenterol 1994:10:243-248.
41. Michel G, Ritter A, Gerken G, et al. Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 1992:339:267-269.
42. Miyakawa H, Kako M. Type 2 autoimmune hepatitis (AIH) in Japan and the relation to HCV infection (Abst). Hepatology 1992:16:569.
43. Blanchette VS, Vorstman E, Shore A, et al. Hepatitis C infection in children with hemophilia A and B. Blood 1991:78:285-289.
44. Vranckx R. Sexual transmission of hepatitis C virus (letter). Br Med J 1991:303:783.
45. Melbye M, Biggar RJ, Wantzin P, et al. Sexual transmission of hepatitis C virus: Cohort study (1981-9) among European homosexual men. Br Med J 1990:301:210-212.
46. Riestra S, Carcaba V. Hepatitis C virus: Evidence for sexual transmission (letter). Br Med J 1991:303:310-311.
47. Tedder RS, Gilson RJC, Briggs M et al. Hepatitis C virus: evidence of sexual transmission. Br Med J 1991:302:1299-1302.
48. Riely CA, Looney JR, Smalley DL, et al. Prevalence and epidemiology of hepatitis C as contrasted with hepatitis B in a sexually transmitted disease clinic (Abst). L Hepatol 1992:16:586.
49. Morris AJ, Rassam SW, Brown D, Dusheiko GM. Detection of HCV RNA in body fluids of patients with chronic hepatitis C infection. Hepatology 1992:16:570.
50. Thieme T, Piacentinis S, Fitchen JH, Beller M. Diagnosis of hepatitis A,B,C and HIV-1, using oral samples, 5th National Forum on AIDS, Hepatitis and other Blood-Borne Diseases. Atlanta, Georgia, March-April 1992; p 81(Abst T-11.4).
51. Dusheiko GM, Smith M, Scheuer PJ. Hepatitis C virus transmitted by human bite (letter). Lancet 1990:336:503-504.
52. Calabrese G, Vagelli G, Guaschino R, Gonella M. Transmission of anti-HCV within the household of hemodialysis patients (letter). Lancet 1991:338:1466.
53. Nishiguchi S, Kuroki T, Fukuda K, et al. Vertical transmission of hepatitis C virus (HCV) confirmed by partial sequencing of the HCV genome in mothers and children (Abst). Hepatology 1992:16:577.
54. Inoue Y, Miyamura T, Unayama T, Takahashi K, Saito I. Maternal transfer of HCV. Nature 1991:353:609.
55. Degos F, Maisonneuve P, Thiers V, et al. Neonatal transmission of HCV from mother with chronic hepatitis (letter). Lancet 1991;338:758.
56. Chou WS, Sheu L, et al. Household contact might be a minor route to transmit hepatitis С virus infection in the family (Abst). Hepatology 1992;16:523.
57. Oshita M, Hayashi N, Kasahara A, et al. Intrafamiliar transmission of hepatitis С virus (Abst). Hepatology 1992;16;581.
58. Deny P, Roulot D, Asselot C, et al. Low rate of hepatitis С virus (HCV) transmission within the family (letter). J Hepatol 1992;14:409-410.
59. Nishiguchi S, Kuroki T, Fukuda K, et al. Familial clustering of HCV (letter). Lancet 1992;339:1486.
60. Akahane Y, Aikawa T, Sugai Y, et al. Transmission of HCV between spouses (letter). Lancet 1992;339:1059-1060.
61. Jochen ABB. Occupationally acquired hepatitis С virus infection (letter). Lancet 1992;339:304.
62. Herbert A-M, Walker DM, Davies KJ, Bagg J. Occupationally acquired hepatitis С infection (letter). Lancet 1992;339:305.
63. Klein RS, Freeman K, Taylor PE, Stevens CE. Occupational risk for hepatitis С virus infection among New York city dentists. Lancet 1991; 338:1439-1542.
64. De Luca M, Ascione A, Vacca C, Zarone A. Are health care workers really at risk of HCV infection? (letter) Lancet 1992;339:1364-1365.
65. Mitsui T, lwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needle-stick accident. Hepatology 1992;16:1109-1114.
66. Cummins AJ, Tedder RS. Inadequate information on needlestick accidents (letter). Lancet 1992,339:1178-1179.
67. Simmonds P, McOmish F, McCullough P, et al. Contamination of immunoassay controls with hepatitis C virus (letter). Lancet 1992;339:1607.
68. Ragg M. Transmission of hepatitis C via anaesthetic tubing? (editorial). Lancet 1994,343:1419.
69. Bird AG, Gore SM, Burns SM, Duggie JG. Study of infection with HIV and related risk factors in young offenders’ institutions. Br Med J 1994;308:1092-1095.
70. McBride AJ, Mali I, Clee W. Hepatitis C and injecting drug use in prisons (letter). Br Med J 1994;309:876.
71. Crofts N, Hopper JL, Bowden DS, et al. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993;159:237-241.
72. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis В and non-A, non-B hepatitis. JAMA 1989;262:1201-1205.
73. Attill AF, Rapicetta M, Mele A, et al. Prevalence of anti-HCV antibodies and HCV RNA in an Italian adult general population sample (Abst). Hepatology 1992;16:514.
74. Kuhni P, Seidi S, Stangel W, et al. Antibody to hepatitis C virus in German blood donors (letter). Lancet 1989;ii:324.
75. Esteban Jl, Gonzalez A, Hernandez JM, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engi J Med 1990;323:1107-1112.
76. Ranger S, Martin P, Roussanne MC, Denis F. Prevalence of hepatitis C virus antibodies in the general population, and in selected groups of patients in Limoges, France. Gut 1993;34 (Suppl 2):S50-S51.
77. Roudot-Thoraval F, Pawlotsky J-M, Deforges L, Girollet P-P, et al. Anti-HCV seroprevalence in pregnant women in France. Gut 1993;34 (Suppl 2):S55-S56.
78. Lino S, Shimoda K, Hino K, Nishioka K. Prevalence of hepatitis C virus carrier in donors with normal s-ALT in Japan- Relation with history of blood transfusion (Abst). Hepatology 1992;16:547.
79. Yano M, Yatsuhashi H, Inoue O, Inokuchi К, Кода M. Epidemiology and long-term prognosis of hepatitis C virus infection in Japan. Gut 1993;34 (Suppl 2): S13-S16.
80. EI-Zayadi A, Selim O, Rafik M, El-Haddad S. Prevalence of hepatitis C virus among non-A, non-B related chronic liver disease in Egypt (letter). J Hepatol 1992;14:416-417.
81. Roggendorf M, Deinhardt F, Rasshofer R, et al. Antibodies to hepatitis C virus (letter). Lancet 1989;ii:324-325.
82. Alter HJ, Jett BW, Polito AJ, et al. Analysis of the role of hepatitis C virus in transfusion-associated hepatitis. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and Liver Disease. Baltimore: Williams & Wikins,1991;396-402.
83. Alter MJ. Community-acquired viral hepatitis В and C in the United States. Gut 1993;34 (Suppl 2):S17-S19. 84. Romeo R, Rumi MG, Soffredini R, et al. Hepatitis C virus serotypes and viremia in Italian patients with chronic infection (Abst 554). Hepatology 1994;20:235A.
85. Lau JYN, Davis GL, Ohno T, et al. Application of hepatitis С virus (HCV) subtyping in chronic hepatitis С in the United States (Abst 370). Hepatology 1993;18:149A.
86. McOmish F, Yap PL, Dow ВС, et al. Geographical distribution of hepatitis С virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994:32:884-892.
87. Ohno T, Mizokami M, Orito E, et al. A new hepatitis С virus (HCV) genotyping system that allows for the identification of HCV genotype 3, 4a and 5a (Abst 588). Hepatology 1994;20:243A.
88. Takada N, Takase S, Takada A, Date T. HCV genotypes in different countries (letter). Lancet 1992;339:808.
89. Alberti A, Realdi G. Parenterally-acquired non-A, non-B (type C) hepatitis. In: Mcintyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J. Oxford Textbook of cliniccil hepatology. Oxford: Oxford University Press, 1991;605-617.
90. Gerlich WH, Thornssen A. Terminology, structure, and laboratory diagnosis of hepatitis viruses. In: Mcintyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J. Oxford Textbook of Clinical Hepatology. New York: Oxford University Press, 1991:537-565.
91. Bernuau J, Benhamou J-P. Fulminant and subfulminant liver failure. ln:Mclntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. New York: Oxford University Press, 1991:923-942.
92.Yoshiba M, Dehara K, Inoue K, Okamoto H, Mayumi M. Contribution of hepatitis С virus to non-A, non-B fulminant hepatitis in Japan. Hepatology 1994:19:829-835.
93. Gimson AES, White YS, Eddleston AL. Clinical and prognostic differences in fulminant hepatitis type А, В and non-A, non-B. Gut 1983;24:1194-1198.
94. Feray C, Gigou M, Samuel D, et al. Hepatitis С (HCV) RNA and hepatitis В (HBV) DNA in patients with fulminant hepatitis. Hepatology 1991:14 (pt 2):130A.
95. Lau JYN. Hepatitis C virus: From epidemiology and molecular virology to immunology. Hepatology 1994:20:760-762.
96. Tanno H, Fay O, Fay F, Sapene C. Absence of relapse in patients with type C chronic hepatitis (Abst). J Hepatol 1992:16:600.
97. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Therap 1994:16:334-343.
98. Ware FE, Bungay K, Gandek B, Bayliss M. Assessment of the health-related quality of life (HQL) of patients with chronic hepatitis C (CHC). Abstract. Digestive Disease Week, May 14-20, 1994; New Orleans, LA, USA.
99. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viremia and liver disease in symptom-free individuals with anti-hepatitis C virus. Lancet 1992:340:697-698.
100. Persico M, Romano M. Alanine aminotransferase measuremems and histological disease in hepatitis C (letter). Lancet 1993:342:1369-1370.
101. Jeffers IJ, Cheinquer H, Hunt W, et al. Correlation of ALT levels and severity of hepatic histology with a new quantitative HCV RNA method in patients with chronic hepatitis C (Abst). J Hepatol 1992:16:551.
102. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. J Hepatol 1992:16:273-281.
103. Yano M, Yatsuhashi H, Inoue О, Кода M. Epidemiology of hepatitis C virus in Japan: role in chronic liver disease and hepatocellular carcinoma. J Gastroenterol Hepatol 1991;Suppl 1:31-35.
104. Colombari R, Dhillon AP, Piazzola E, et al. Chronic hepatitis in multiple virus infection: Histopathological evaluation (Abst). J Hepatol 1992:16:524.
105. Liaw YF, Chien RN, Huang MJ, et al. Hepatic C virus suppresses hepatitis В virus replication: An immunohistologic study (Abst). J Hepatol 1992:16:562.
106. Liaw YF, Chien RN, Chen TJ, Sheen IS, Chu CH. Concurrent hepatitis C virus and hepatitis delta virus superinfection in patients with chronic hepatitis В virus infection. J Med Virol 1992:37:294-297.
107. Smith HM, Daniels HM, Tibbs CJ, Lau JYN, Williams R. HCV in non replicative chronic HBV infection (letter). J Hepatol 1992:14:405.
108. Fong TL, Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease Baltimore: Williams & Wikins, 1991:413-415.
109. Kakiamani E, et al. Hepatitis B and C viruses and their interaction in the origin of hepaticellular carcinoma. JAMA 1991;265:1974-1976.
110. Colombo M, Rumi MG, Donate MF, et al. Hepatitis С antibody in patients with chronic liver disease and hepatocellular carcinoma. Dig Dis Sci 1991;36:1130-1133.
111. Pagliaro L, Craxi A. Approach to the patient with viral hepatitis. ln:Mclntyre N, Berihamou J-P, Birche.r J, Rizzeto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. New York: Oxford University Press, 1991; pp 646-656.
112. Degos F, Degott C, Benhamou JP. Liver biopsy. In: Mcintyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. New York: Oxford University Press, 1991; pp 320-324.
113. Hiramatsu N, Hayashi N, Haruna Y, et al. Expression of HCV-related antigen and liver damage in patients with chronic hepatitis С (Abst). J Hepatol 1992;16:544.
114. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
115. Knodell RG, Ishak KG, Black WC. et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
116. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-415.
117. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N engi J Med 1993;328:1797-1801.
118. Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991;86:335-338.
119. Feidman M. Hepatitis С virus and hepatocellular carcinoma: Additional evidence of causal link. Gastroenterol 1991;100:1145-1146.
120. Stella de Mitri M, Poussin K, Pontisso P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-415.
121. Farinati F, Fagiuoli S, DeMaria N, et al. Anti-hepatitis С virus positive hepatocellular carcinoma in cirrhosis. Prevalence, risk factors and clinical features. J Hepatol 1992;14:183-187.
122. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialoadenitis of Sjogren’s syndiome associated with chronic hepatitis C virus liver disease. Lancet 1992;339:321-323.
123. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryo-globulinemia. Ann Intern Med 1992;117:573-577.
124. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type 2 cryoglobulinemia. N Engi J Med 1992;327:1490-1495.
125. Levey JM, Bjornsson B, Banner B, et al. Mixed cryoglobulinemia in chronic hepatitis C infection. A clinicopathologic analysis of 10 cases and review of recent literature. Medicine 1994;73:53-67.
126. Disdier P, Harle J-R, Weiller P-J. Cryoglobulinemia and hepatitis C virus infection (letter). Lancet 1991;338:139-144.
127. Ferri C, Marzo E, Longombardo G, et al. Interferon alfa-2b in mixed cryoglobulinemia: A controlled crossover trial. Gut 1993;34 (Suppl 2): S144-S145.
128. Obaid-Shakil A, Di Bisceglie AM. Extra-hepatic manifestations of chronic viral hepatitis. Internista 1994;2:139-144.
129. Pingel S, Hartmann H, Ramadori G. Essential mixed cryoglobulinemia (EMC) in case of chronic hepatitis C. Successful treatment with interferon alpha. J Gastroenterol 1994:32:584-588.
130. Herrero C, Vicente A, Bruguerf M, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993;341:788-789.
131. Murphy A, Dooley S, Hilary IB, Murphy GM. HCV infection in porphyria cutanea tarda (letter). Lancet 1993;341:1534-1535.
132. Lacour J, Bodokh I, Castenet J, et al. Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol 1993;128:121-123.
133. Nishiguchi S, Kuroki T, Yabusako T, et al. Detection of hepatitis C virus antibodies and hepatitis C virus RNA in patients with alcoholic liver disease. Hepatology 1991;14:985-989.
134. Nalpas B, Thiers V, Pol S, et al. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol 1992;14:381-384.
135. Poynard T, Aubert A, Lazizi Y, et al. Is hepatitis C virus infection a case of cirrhosis among drinkers? In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wikins, 1991;448-450.
136. Mendenhall CL, Seeff L, Diehl AM, et al. Hepatitis В and С serological markers: Relationship to alcoholic hepatitis and cirrhosis. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and Liver Disease. Baltimore: Williams & Wikins, 1991;448-450.
137. Dienes HP, Hutteroth T, Hess G, Meuer SC. Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis В and non-A, non-B. Hepatology 1987;776:1317-1325.
138. GonzaIez-Perralta RP, Fang JWS, Davis GL, et al. Immunopathobiology of chronic hepatitis С virus infection (Abst 543). Hepatology 1994;20:232A.
139. Lohr HF, Schlaak JK, Kollmannsperger S, et al. The role of cellular immune response in chronic HCV infection (Abst 533). Hepatology 1994;20:232A.
140. Zachoval R, Abb J, Zachoval V, Eisenburg J, Pape GR, Paumgartner G, Deinhardt F. Interferon alpha in hepatitis В and non-A, non-B. Defective production by peripheral blood mononuclear cells in chronic infection and development of serum interferon in acute disease. I Hepatol 1988;6:364.
141. Isaac A, Lindenmann J. Virus interference: 1. The interferon. Proc R Soc Lond (Biol) 1957:147:258-273.
142. Dianzani F, Antonelli G, Capobiachi MR. The biological basis for clinical use of interferon. J Hepatol 1990;11 (Suppll):S5-S10.
143. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau J-M. Comparative efficacy of interferon alfa in cirrhoticand noncirrhotic patients with non-A, non-B, С hepatitis. Gastioenterol 1994;106:686-690.
144. Poynard T, Multicenter Study Group. A randomized clinical of 18 months therapy with alpha-2b interferon (IFN 2b) in patients with chronic hepatitis С (Abst). J Hepatol 1993;18 (Suppl 1): S52.
145. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis С after treatment with interferon alpha-2b for 60 weeks. Hepatology 1994;19:280-285.
146. Poynard T, Bedossa P, Mathurin P, et al. Efficacy of long-term recombinant interferon alfa in patients with chronic hepatitis C. A clinical, biological, histological and immunohistological study. Gastroenterol Clin Biol 1991;15:615-619.
147. Shindo M, DiBisceglie AM, Hoofnagle JH. Long- term follow-up of patients with chronic hepatitis С treated with alpha-interferon. Hepatology 1992;15:1013-1026.
148. Regenstein F, Towbin B. Viral hepatitis: The emerging role of antiviral drugs. Drug Ther 1993; Feb:18-37.
149. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis С with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engi J Med 1989; 321:1501-1506.
150. Di Bisceglie AM, Martin P, Kassaniades C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engi .1 Med 1989; 321:1506-1510.
151. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alfa-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial in France. Hepatology 1991;13:393-397.
152. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU inlerferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterol 1991;101:497-502.
153. Saracco G, Rosina F, Torrani Cerenzia MT, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11 (Suppl 1):S43-S49.
154. Piazza M, Orlando R, Tosone G, et al. Treatment of chronic hepatitis C with recombinant interferon alfa-2b.Gut 1993;34 (Suppl 2):S128-S129.
155. Lino S. High dose interferon treatment in chronic hepatitis C. Gut 1993;34 (Suppl 2):S114-S118.
156. Lindsay KL, Davis GL, Schiff E, et al. Long-term response to higher doses of interferon (IFN) alfa-2b treatment of patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 1993;18 (4, Part2):149A.
157. Lok ASF, Cheung R, Chan R. Persistence of HCV viremia in chronic HCV infection (Abst). J Hepatol 1992;16:563.
158. Varagona G, Brown D, Kibler H, et al. Response, relapse and retreatment rates and viremia in chronic hepatitis C treated with alpha 2-b interferon, a phase 3 study. Eur J Gastroenterol Hepatol 1992;4:707-712.
159. Saracco G, Rizzetto M. The results of a long-term follow-up study of patients with chronic HCV infection treated with interferon alfa-2b. Viral Hepatitis Management: Standards for the future. Abstract Book, Cannes, 1992. Macclesfield, UK: Adelphi Communications Ltd, 1992;90-91.
160. Fried MW, Hoofnagle JH, Di Bisceglie AM. Alpha interferon treatment for chronic hepatitis C: Experience at the National Institutes of Health. Viral Hepatitis Management: Standards foi the future. Abstract Book, Cannes, 1992;98.
161. DeBac C, Grimaldi F, Clementi C, et al. Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. Gut 1993;34 (Suppl 2):S135.
162. Diodati G, Bonetti P, Scaccabrarozzi S, et al. Changes of antibodies to different epitopes of HCV during interferon therapy of chronic NANB hepatitis (Abst). Hepatology 1992;16:530.
163. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the aminoter-minal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992;16:619-624.
164. Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of the patients having different types of patients C virus genomes. J Hepatol 1992;14:35-40.
165. Marcillin P, Martinot M, Pouteau M, et al. HCV genotype and pretreatment serum HCV RNA level are the main and independent prognosis factors of sustained response to interferon in chronic hepatitis C (Abst 445). Hepatology 1994;20:208A.
166. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
167. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alfa therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992,16:293-299.
168. Makris M, Preston FE, Triger DR, et al. A randomized controlled trial of recombinant interferon alfa in chronic hepatitis C in hemophiliacs. Blood 1991;78:1672-1677.
169. Peerlinck K, Willems M, Sheng L, et al. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment. Br J Haematol 1994;86:816-819.
170. Di Marco V, Lo lacono O, Carpa M, et al. Alpha interferon treatment of chronic hepatitis C in betta-thalassaemia. Gut 1993;34 (Suppl 2): S142-S143.
171. Tassopoulos NC, Koutelou MG, Papatheodoridis G, et al. Treatment of acute non-A, non-B hepatitis with interferon alpha-2b (letter). Infection 1992:20:242.
172. Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon alfa-2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
173. Colombo M, Lampertico P, Rumi M. Multicentre randomized controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion. Gut 1993;34 (Suppl 2):S141.
174. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon alfa therapy in hepatitis C virus infection. Hepatology 1994;19:1088-1094.
175. Pagliaro L, Craxi A, Cammaa C, et al. Interferon alpha for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 1994;19:820-828.
176. Dusheiko GM, Roberts JA. Treatment of chronic type В and C hepatitis with alpha interferon. An economic evaluation. Poster presented at the 29th Annual Meeting of the European Association for the Study of the Liver, Athens, Greece, September 7-10, 1994.
177. Maynard A. The design of future cost-benefit studies. Am Heart J 1990;761-765.
178. Sherman KE, Sjogren MH, Creager RL, et al. Hepatitis C RNA response to combined therapy with thymosin alpha-1 and interferon (Abst 444). Hepatology 1994;20:207A.
179. Nancy P. Lam, Avidan U. Neumann, David R. Gretch, et al. Dose-Dependent Acute Clearance of Hepatitis C Genotype 1 Virus With Interferon Alfa. Hepatology 1997; 26: 226-231.
180. S. J. Cotier, D.R. Gretch, A.M. Larson, et al. Retreatment of Hepatitis C virus (HCV) inlection with daily high dose interferon therapy. Hepatology, 1997, 26, 4, Pt: 1146.
181. N.P. Laam, A.U. Neumann, H. Dahari, et al. Early viral desline slopes during daily high dose interferon (IFR) are predictive markers of subsequent virologic response. Hepatology, 1998, 28, 4, Pt: 940.
182. Schalm S, Hansen В, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. // J. Hepatology 1997; 26:961-966.
183. Reichard O, Norkrans G, Fryden A, et al. Randomised double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. // Lancet 1998; 351:83-87.